Jonathan S. Zager
Expertise in
14
conditions

Dr. Jonathan S. Zager

General Surgery
Moffitt Cancer Center, Magnolia Campus
12902 Usf Magnolia Dr, 
Tampa, FL 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
Expertise in
14
conditions
Moffitt Cancer Center, Magnolia Campus
12902 Usf Magnolia Dr, 
Tampa, FL 

Overview

Jonathan Zager is a General Surgeon practicing medicine in Tampa, Florida.

Dr. Zager is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Melanoma, Merkel Cell Carcinoma, Adult Soft Tissue Sarcoma, Lymphadenectomy, and Liver Embolization.

He is actively involved in clinical research, co-authoring 286 peer reviewed articles and participating in 13 clinical trials. Dr. Zager is currently accepting new patients.

Specialties

General Surgery

Licenses

Surgery in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

Moffitt Cancer Center, Magnolia Campus
12902 Usf Magnolia Dr, Tampa, FL 33612
Other Locations
Moffitt Cancer Center, Richard M. Schulze Family Foundation Outpatient Center at McKinley Campus
10920 McKinley Dr, Tampa, FL 33612

Additional Areas of Focus

Dr. Zager has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma: Safety and Biomarker Analysis
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma: Safety and Biomarker Analysis
Enrollment Status: Recruiting
Publish Date: June 25, 2026
Intervention Type: Drug
Study Drug: Cemiplimab
Study Phase: Phase 1
An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C/D Melanoma Patients
An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C/D Melanoma Patients
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Drug, Procedure
Study Drugs: Daromun, Adjuvant Therapy
Study Phase: Phase 3
Neoadjuvant Immunotherapy With Intratumoral Tavokinogene Telseplasmid (Tavo) Plus Electroporation in Combination With Intravenous Nivolumab in Patients With Operable Locally- Regionally Advanced Melanoma
Neoadjuvant Immunotherapy With Intratumoral Tavokinogene Telseplasmid (Tavo) Plus Electroporation in Combination With Intravenous Nivolumab in Patients With Operable Locally- Regionally Advanced Melanoma
Enrollment Status: Completed
Publish Date: June 29, 2026
Intervention Type: Device, Drug
Study Drugs: Tavo, Nivolumab
Study Phase: Phase 2
Phase I Study of Escalating Doses of XL888 With Vemurafenib Plus Cobimetinib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma
Phase I Study of Escalating Doses of XL888 With Vemurafenib Plus Cobimetinib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: March 02, 2026
Intervention Type: Drug
Study Drugs: XL888, Vemurafenib, Cobimetinib
Study Phase: Phase 1
A Pilot Clinical Trial Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
A Pilot Clinical Trial Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
Enrollment Status: Completed
Publish Date: August 19, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Nivolumab, CD137, Cyclophosphamide, Fludarabine, Tumor- Infiltrating Lymphocytes Infusion, Interleukin-2
Study Phase: Early Phase 1
A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma
A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Combination product
Study Drug: Melphalan/Hepatic Device System
Study Phase: Phase 3
An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: December 21, 2023
Intervention Type: Combination product
Study Phase: Phase 3
A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination With Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma
A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination With Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma
Enrollment Status: Unknown
Publish Date: November 21, 2023
Intervention Type: Drug
Study Drugs: PV-10, Pembrolizumab
Study Phase: Phase 1/Phase 2
Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study
Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study
Enrollment Status: Withdrawn
Publish Date: June 28, 2023
Intervention Type: Drug
Study Drug: Pramlintide
Study Phase: Early Phase 1
A Phase 1 Study of HDAC Inhibitor Panobinostat (LBH 589) Administered in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma
A Phase 1 Study of HDAC Inhibitor Panobinostat (LBH 589) Administered in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Completed
Publish Date: January 20, 2023
Intervention Type: Drug
Study Drugs: Panobinostat, Ipilimumab
Study Phase: Phase 1
View 8 Less Clinical Trials

286 Total Publications

Associations Between Pigmentation and the Clinicopathologic and Immune Landscape of Melanoma.
Associations Between Pigmentation and the Clinicopathologic and Immune Landscape of Melanoma.
Journal: The American Journal of dermatopathology
Published: March 20, 2026
Similar Doctors
Expertise in
30
conditions
Dr. Sharona B. Ross
General Surgery
Expertise in
30
conditions
Dr. Sharona B. Ross
General Surgery
Referral may be required

AdventHealth Medical Group General Surgery At Tampa

3000 Medical Park Dr Ste 500, 
Tampa, FL 
 (2.4 miles away)
941-363-6717
Languages Spoken:
English, Hebrew
See accepted insurances
Accepting New Patients
Offers Telehealth

Sharona Ross is a General Surgeon practicing medicine in Tampa, Florida. Dr. Ross is highly rated in 30 conditions, according to our data. Her clinical expertise encompasses Hiatal Hernia, Gastroesophageal Reflux Disease (GERD), Hernia, Pancreaticoduodenectomy, and Gallbladder Removal. Dr. Ross is currently accepting new patients.

Expertise in
30
conditions
Dr. Iswanto L. Sucandy
General Surgery
Expertise in
30
conditions
Dr. Iswanto L. Sucandy
General Surgery
Referral may be required

AdventHealth Medical Group General Surgery At Tampa

3000 Medical Park Dr Ste 500, 
Tampa, FL 
 (2.4 miles away)
813-615-7030
Languages Spoken:
English, Bahasa
See accepted insurances
Accepting New Patients
Offers Telehealth

Iswanto Sucandy is a General Surgeon practicing medicine in Tampa, Florida. Dr. Sucandy is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Cholangiocarcinoma (Bile Duct Cancer), Liver Cancer, Bile Duct Stricture, Hepatectomy, and Gallbladder Removal. Dr. Sucandy is currently accepting new patients.

Expertise in
22
conditions
Dr. Mokenge P. Malafa
General Surgery
Expertise in
22
conditions
Dr. Mokenge P. Malafa
General Surgery
Referral may be required

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
813-773-4494
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients
Offers Telehealth

Mokenge Malafa is a General Surgeon practicing medicine in Tampa, Florida. Dr. Malafa is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Familial Pancreatic Cancer, Pancreatic Adenoma, Pancreatectomy, and Small Bowel Resection. Dr. Malafa is currently accepting new patients.

Frequently Asked Questions about Dr. Jonathan S. Zager

How do I make an appointment with Dr. Jonathan S. Zager?

You can book an appointment with Dr. Jonathan S. Zager by calling their office at 813-566-0889. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jonathan S. Zager a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jonathan S. Zager is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jonathan S. Zager specialize in?

While Dr. Jonathan S. Zager is a General Surgery, they have specific expertise in Melanoma, Merkel Cell Carcinoma, and Adult Soft Tissue Sarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within General Surgery.

Does Dr. Jonathan S. Zager participate in research or clinical trials?

Yes. Dr. Jonathan S. Zager has published 286 articles and abstracts on conditions like Melanoma. You can view a list of Dr. Jonathan S. Zager's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jonathan S. Zager accept my insurance?

Dr. Jonathan S. Zager accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 813-566-0889 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zager's expertise for a condition
ConditionClose
View All 27 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile